Rationally designed multi-targeted agents against neurodegenerative diseases

Current Medicinal Chemistry

Volumn 20, Issue 13, 2013, Pages 1662-1672

  Geldenhuys, W J ^a   Van Der Schyf, C J ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Drug discovery; Multi targeted designed drugs; Multifunctional agents; Neurodegenerative diseases

Indexed keywords

4 BENZYL 3 HYDROXY 4 AZAHEXACYCLO[5.4.1.0 2,6 .0 3,10 .0 5,9 .0 8,11]DODECANE; ADENOSINE A2 RECEPTOR; AMANTADINE; AMYLOID BETA PROTEIN; CAFFEINE; DIZOCILPINE; ISTRADEFYLLINE; ISTRADYFILLINE; LADOSTIGIL; MEMANTINE; MEMOQUINE; METAL ION; MITOCHONDRIAL PROTEIN; MITONEET PROTEIN; MOLECULAR SCAFFOLD; N[(5 BENZYLOXY 1 METHYL 1H INDOL 2 YL)METHYL]N METHYLPROP 2 YN 1 AMINE; NEUROPROTECTIVE AGENT; NIMODIPINE; PHENCYCLIDINE; PIOGLITAZONE; PROTECTIVE AGENT; RASAGILINE; RESVERATROL; RIVASTIGMINE; ROSIGLITAZONE; STILBENE; TROGLITAZONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CHELATION; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; IC 50; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION;

AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM CHANNEL BLOCKERS; CHOLINESTERASE INHIBITORS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 84877948856     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990112     Document Type: Article

References (123)

1. Van der Schyf, C.J., The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev. Clin. Pharmacol., 2011, 4(3), 293-298.
2. Piau, A.; Nourhashemi, F.; Hein, C.; Caillaud, C.; Vellas, B., Progress in the development of new drugs in Alzheimer's disease. J. Nutr. Health Aging, 2011, 15(1), 45-57.
3. Schwarz, S.; Froelich, L.; Burns, A., Pharmacological treatment of dementia. Curr. Opin. Psychiatry, 2012, 25(6), 542-550.
4. Morphy, R.; Kay, C.; Rankovic, Z., From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9(15), 641-651.
5. Roth, B.L.; Sheffler, D.J.; Kroeze, W.K., Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov., 2004, 3(4), 353-359.
6. Pruss, R.M., Phenotypic screening strategies for neurodegenerative diseases: A pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol. Disord. Drug Targets, 2010, 9(6), 693-700.
7. Youdim, M.B.; Geldenhuys, W.J.; Van der Schyf, C.J., Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat. Disord., 2007, 13 Suppl 3, S281-291.
8. Geldenhuys, W.J.; Youdim, M.B.; Carroll, R.T.; Van der Schyf, C.J., The emergence of designed multiple ligands for neurodegenerative disorders. Prog. Neurobiol., 2011, 94(4), 347-359.
9. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C., Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51(3), 347-372.
10. Plun-Favreau, H.; Lewis, P.A.; Hardy, J.; Martins, L.M.; Wood, N.W., Cancer and neurodegeneration: Between the devil and the deep blue sea. PLoS Genet., 2010, 6(12), e1001257.
11. Pardridge, W.M., Blood-brain barrier delivery. Drug Discov. Today, 2007, 12(1-2), 54-61.
12. Martin, L.J., Biology of mitochondria in neurodegenerative diseases. Prog. Mol. Biol. Transl. Sci., 2012, 107, 355-415.
13. Hurley, M.J.; Dexter, D.T., Voltage-gated calcium channels and Parkinson's disease. Pharmacol. Ther., 2012, 133(3), 324-333.
14. Surmeier, D.J., Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol., 2007, 6(10), 933-938.
15. Kemp, J.A.; McKernan, R.M., NMDA receptor pathways as drug targets. Nat. Neurosci., 2002, 5 Suppl, 1039-1042.
16. Lippert, K.; Welsch, M.; Krieglstein, J., Over-additive protective effect of dizocilpine and NBQX against neuronal damage. Eur. J. Pharmacol., 1994, 253(3), 207-213.
17. Krieglstein, J.; Lippert, K.; Poch, G., Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology, 1996, 35(12), 1737-1742.
18. Rodda, J.; Carter, J., Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ, 2012, 344, e2986.
19. Geldenhuys, W.J.; Malan, S.F.; Bloomquist, J.R.; Marchand, A.P.; Van der Schyf, C.J., Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: A focus on pentacycloundecane derivatives. Med. Res. Rev., 2005, 25(1), 21-48.
20. Parsons, C.G.; Danysz, W.; Quack, G., Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-A review of preclinical data. Neuropharmacology, 1999, 38(6), 735-767.
21. Danysz, W.; Parsons, C.G.; Kornhuber, J.; Schmidt, W.J.; Quack, G., Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev., 1997, 21(4), 455-468.
22. Stuiver, B.T.; Douma, B.R.; Bakker, R.; Nyakas, C.; Luiten, P.G., In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: Combined therapy and temporal course of protection. Neurodegeneration, 1996, 5(2), 153-159.
23. Kiewert, C.; Hartmann, J.; Stoll, J.; Thekkumkara, T.J.; Van der Schyf, C.J.; Klein, J., NGP1-01 is a brain-permeable dual blocker of neuronal voltage-and ligand-operated calcium channels. Neurochem. Res., 2006, 31(3), 395-399.
24. Geldenhuys, W.J.; Malan, S.F.; Bloomquist, J.R.; Van der Schyf, C.J., Structure-activity relationships of pentacycloundecylamines at the N-methyl-D-aspartate receptor. Bioorg. Med. Chem., 2007, 15(3), 1525-1532.
25. Van der Schyf, C.J.; Squier, G.J.; Coetzee, W.A., Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. Pharmacol. Res. Commun., 1986, 18(5), 407-417.
26. Malan, S.F.; Dyason, K.; Wagenaar, B.; Van Der Walt, J.J.; Van Der Schyf, C.J., The structure and ion channel activity of 6-benzylamino-3-hydroxyhexa- cyclo[6.5.0.0(3,7).0(4,12).0(5,10).0 (9,13)]tridecane. Arch. Pharm. (Weinheim), 2003, 336(2), 127-133.
27. Malan, S.F.; Van der Walt, J.J.; Van der Schyf, C.J., Structureactivity relationships of polycyclic aromatic amines with calcium channel blocking activity. Arch. Pharm. (Weinheim), 2000, 333(1), 10-16.
28. Kashiwagi, K.; Masuko, T.; Nguyen, C.D.; Kuno, T.; Tanaka, I.; Igarashi, K.; Williams, K., Channel blockers acting at N-methyl-Daspartate receptors: Differential effects of mutations in the vestibule and ion channel pore. Mol. Pharmacol., 2002, 61(3), 533-545.
29. Hao, J.; Mdzinarishvili, A.; Abbruscato, T.J.; Klein, J.; Geldenhuys, W.J.; Van der Schyf, C.J.; Bickel, U., Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. Brain Res., 2008, 1196, 113-120.
30. Mdzinarishvili, A.; Geldenhuys, W.J.; Abbruscato, T.J.; Bickel, U.; Klein, J.; Van der Schyf, C.J., NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci. Lett., 2005, 383(1-2), 49-53.
31. Gaasch, J.A.; Geldenhuys, W.J.; Lockman, P.R.; Allen, D.D.; Van der Schyf, C.J., Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures. Neurochem. Res., 2007, 32(10), 1686-1693.
32. Gaasch, J.A.; Lockman, P.R.; Geldenhuys, W.J.; Allen, D.D.; Van der Schyf, C.J., Brain iron toxicity: Differential responses of astrocytes, neurons, and endothelial cells. Neurochem. Res., 2007, 32(7), 1196-1208.
33. Luedtke, R.R.; Perez, E.; Yang, S.H.; Liu, R.; Vangveravong, S.; Tu, Z.; Mach, R.H.; Simpkins, J.W., Neuroprotective effects of high affinity sigma 1 receptor selective compounds. Brain Res., 2012, 1441, 17-26.
34. Banister, S.D.; Moussa, I.A.; Jordan, M.J.; Coster, M.J.; Kassiou, M., Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling. Bioorg. Med. Chem. Lett., 2010, 20(1), 145-148.
35. Kassiou, M.; Nguyen, V.H.; Knott, R.; Christie, M.; Hambley, T.W., Trishomocubanes, a new class of selective and high affinity ligands for the simga binding site. Bioorg. Med. Chem. Lett., 1996, 6, 595-600.
36. Liu, X.; Banister, S.D.; Christie, M.J.; Banati, R.; Meikle, S.; Coster, M.J.; Kassiou, M., Trishomocubanes: Novel sigma ligands modulate cocaine-induced behavioural effects. Eur. J. Pharmacol., 2007, 555(1), 37-42.
37. Liu, X.; Kassiou, M.; Christie, M.; Hambley, T.W., Trishomocubanes: Requirements for sigma receptor binding and subtype selectivity. Aust. J. Chem., 2001, 54, 157-163.
38. Liu, X.; Mattner, F.; Katsifis, A.; Christie, M.; Kassiou, M., Influence of trishomocubanes on sigma receptor binding of N-(1-benzyl-piperidin-4-yl)-4- [123I]iodobenzamide in vivo in the rat brain. Med. Chem., 2005, 1(1), 31-38.
39. Liu, X.; Nuwayhid, S.; Christie, M.J.; Kassiou, M.; Werling, L.L., Trishomocubanes: Novel sigma-receptor ligands modulate amphetamine-stimulated [3H]dopamine release. Eur. J. Pharmacol., 2001, 422(1-3), 39-45.
40. Nguyen, V.H.; Mardon, K.; Kassiou, M.; Christie, M.D., In vitro and in vivo characterisation of [3H]ANSTO-14 binding to the sigma 1 binding sites. Nucl. Med. Biol., 1999, 26(2), 209-215.
41. Campdelacreu, J., Parkinson disease and Alzheimer disease: Environmental risk factors. Neurologia, 2012, [Epub ahead of Print].
42. Geldenhuys, W.J.; Bishayee, A.; Darvesh, A.S.; Carroll, R.T., Natural products of dietary origin as lead compounds in virtual screening and drug design. Curr. Pharm. Biotechnol., 2012, 13(1), 117-124.
43. Chen, J.F.; Xu, K.; Petzer, J.P.; Staal, R.; Xu, Y.H.; Beilstein, M.; Sonsalla, P.K.; Castagnoli, K.; Castagnoli, N., Jr.; Schwarzschild, M.A., Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci., 2001, 21(10), RC143.
44. Chen, J.F.; Steyn, S.; Staal, R.; Petzer, J.P.; Xu, K.; Van Der Schyf, C.J.; Castagnoli, K.; Sonsalla, P.K.; Castagnoli, N., Jr.; Schwarzschild, M.A., 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J. Biol. Chem., 2002, 277(39), 36040-36044.
45. Petzer, J.P.; Steyn, S.; Castagnoli, K.P.; Chen, J.F.; Schwarzschild, M.A.; Van der Schyf, C.J.; Castagnoli, N., Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg. Med. Chem., 2003, 11(7), 1299-1310.
46. Muller, C.E.; Geis, U.; Hipp, J.; Schobert, U.; Frobenius, W.; Pawlowski, M.; Suzuki, F.; Sandoval-Ramirez, J., Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists. J. Med. Chem., 1997, 40(26), 4396-4405.
47. Muller, C.E.; Sauer, R.; Geis, U.; Frobenius, W.; Talik, P.; Pawlowski, M., Aza-analogs of 8-styrylxanthines as A2A-adenosine receptor antagonists. Arch. Pharm. (Weinheim), 1997, 330(6), 181-189.
48. Pretorius, J.; Malan, S.F.; Castagnoli, N., Jr.; Bergh, J.J.; Petzer, J.P., Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg. Med. Chem., 2008, 16(18), 8676-8684.
49. van den Berg, D.; Zoellner, K.R.; Ogunrombi, M.O.; Malan, S.F.; Terre'Blanche, G.; Castagnoli, N., Jr.; Bergh, J.J.; Petzer, J.P., Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorg. Med. Chem., 2007, 15(11), 3692-3702.
50. Milczek, E.M.; Binda, C.; Rovida, S.; Mattevi, A.; Edmondson, D.E., The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. FEBS J., 2011, 278(24), 4860-4869.
51. Binda, C.; Mattevi, A.; Edmondson, D.E., Structural properties of human monoamine oxidases A and B. Int. Rev. Neurobiol., 2011, 100, 1-11.
52. Culman, J.; Nguyen-Ngoc, M.; Glatz, T.; Gohlke, P.; Herdegen, T.; Zhao, Y., Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: A preclinical stroke trial. Exp. Neurol., 2012, 238(2), 243-253.
53. Culman, J.; Zhao, Y.; Gohlke, P.; Herdegen, T., PPAR-gamma: Therapeutic target for ischemic stroke. Trends Pharmacol. Sci., 2007, 28(5), 244-249.
54. Carta, A.R.; Pisanu, A., Modulating Microglia Activity with PPAR-gamma Agonists: A Promising Therapy for Parkinson's Disease? Neurotox. Res., 2013, 23(2), 112-123.
55. Breidert, T.; Callebert, J.; Heneka, M.T.; Landreth, G.; Launay, J.M.; Hirsch, E.C., Protective action of the peroxisome proliferatoractivated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem., 2002, 82(3), 615-624.
56. Dehmer, T.; Heneka, M.T.; Sastre, M.; Dichgans, J.; Schulz, J.B., Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem., 2004, 88(2), 494-501.
57. Kumar, P.; Kaundal, R.K.; More, S.; Sharma, S.S., Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav. Brain Res., 2009, 197(2), 398-403.
58. Laloux, C.; Petrault, M.; Lecointe, C.; Devos, D.; Bordet, R., Differential susceptibility to the PPAR-gamma agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacol. Res., 2012, 65(5), 514-522.
59. Quinn, L.P.; Crook, B.; Hows, M.E.; Vidgeon-Hart, M.; Chapman, H.; Upton, N.; Medhurst, A.D.; Virley, D.J., The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol., 2008, 154(1), 226-233.
60. Aviles-Olmos, I.; Limousin, P.; Lees, A.; Foltynie, T., Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain, 2013, 136(Pt 2): 374-384.
61. Gillies, P.S.; Dunn, C.J., Pioglitazone. Drugs, 2000, 60(2), 333-343; discussion 344-335.
62. Hunter, R.L.; Dragicevic, N.; Seifert, K.; Choi, D.Y.; Liu, M.; Kim, H.C.; Cass, W.A.; Sullivan, P.G.; Bing, G., Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem., 2007, 100(5), 1375-1386.
63. Akar, C.; Kalinin, S.; Gavrilyuk, V.; Spagnolo, A.; Weinber, G.; Feinstein, D.L., Receptor-independent metabolic effects of thiazolidinediones in astrocytes. Open Cancer Immunol. J., 2010, 3, 36-40.
64. Geldenhuys, W.J.; Darvesh, A.S.; Funk, M.O.; Van der Schyf, C.J.; Carroll, R.T., Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg. Med. Chem. Lett., 2010, 20(17), 5295-5298.
65. Cronet, P.; Petersen, J.F.; Folmer, R.; Blomberg, N.; Sjoblom, K.; Karlsson, U.; Lindstedt, E.L.; Bamberg, K., Structure of the PPARalpha and-gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure, 2001, 9(8), 699-706.
66. Montanari, R.; Saccoccia, F.; Scotti, E.; Crestani, M.; Godio, C.; Gilardi, F.; Loiodice, F.; Fracchiolla, G.; Laghezza, A.; Tortorella, P.; Lavecchia, A.; Novellino, E.; Mazza, F.; Aschi, M.; Pochetti, G., Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: A new region of the hydrophobic pocket could be exploited for drug design. J. Med. Chem., 2008, 51(24), 7768-7776.
67. Gampe, R.T., Jr.; Montana, V.G.; Lambert, M.H.; Miller, A.B.; Bledsoe, R.K.; Milburn, M.V.; Kliewer, S.A.; Willson, T.M.; Xu, H.E., Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell, 2000, 5(3), 545-555.
68. Kwok, J.B., Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics, 2010, 2(5), 671-682.
69. Pithadia, A.S.; Lim, M.H., Metal-associated amyloid-beta species in Alzheimer's disease. Curr. Opin. Chem. Biol., 2012, 16(1-2), 67-73.
70. Guilarte, T.R., Manganese and Parkinson's disease: A critical review and new findings. Cien Saude Colet, 2011, 16, (11), 4549-4566.
71. Lee, D.W.; Andersen, J.K., Iron elevations in the aging Parkinsonian brain: A consequence of impaired iron homeostasis? J. Neurochem., 2010, 112(2), 332-339.
72. Magaki, S.; Raghavan, R.; Mueller, C.; Oberg, K.C.; Vinters, H.V.; Kirsch, W.M., Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias. Neurosci. Lett., 2007, 418(1), 72-76.
73. Hindo, S.S.; Mancino, A.M.; Braymer, J.J.; Liu, Y.; Vivekanandan, S.; Ramamoorthy, A.; Lim, M.H., Small molecule modulators of copper-induced Abeta aggregation. J. Am. Chem. Soc., 2009, 131(46), 16663-16665.
74. Kung, H.F.; Lee, C.W.; Zhuang, Z.P.; Kung, M.P.; Hou, C.; Plossl, K., Novel stilbenes as probes for amyloid plaques. J. Am. Chem. Soc., 2001, 123(50), 12740-12741.
75. Kung, M.P.; Hou, C.; Zhuang, Z.P.; Zhang, B.; Skovronsky, D.; Trojanowski, J.Q.; Lee, V.M.; Kung, H.F., IMPY: An improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res., 2002, 956(2), 202-210.
76. Choi, J.S.; Braymer, J.J.; Nanga, R.P.; Ramamoorthy, A.; Lim, M.H., Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(51), 21990-21995.
77. Yanez, M.; Fraiz, N.; Cano, E.; Orallo, F., Inhibitory effects of cisand trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun., 2006, 344(2), 688-695.
78. Blanchet, J.; Longpre, F.; Bureau, G.; Morissette, M.; DiPaolo, T.; Bronchti, G.; Martinoli, M.G., Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(5), 1243-1250.
79. Lu, K.T.; Ko, M.C.; Chen, B.Y.; Huang, J.C.; Hsieh, C.W.; Lee, M.C.; Chiou, R.Y.; Wung, B.S.; Peng, C.H.; Yang, Y.L., Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem., 2008, 56(16), 6910-6913.
80. Geldenhuys, W.J.; Ko, K.S.; Stinnett, H.; Van der Schyf, C.J.; Lim, M.H., Identification of multifunctional small molecule-based reversible monoamine oxidase inhibitors. Med. Chem. Comm., 2011, 2, 1099-1103.
81. Bolognesi, M.L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C., Multi-targetdirected drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem., 2007, 50(26), 6446-6449.
82. Bolognesi, M.L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C., Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem., 2007, 50(20), 4882-4897.
83. Bolognesi, M.L.; Cavalli, A.; Bergamini, C.; Fato, R.; Lenaz, G.; Rosini, M.; Bartolini, M.; Andrisano, V.; Melchiorre, C., Toward a rational design of multitarget-directed antioxidants: Merging memoquin and lipoic acid molecular frameworks. J. Med. Chem., 2009, 52(23), 7883-7886.
84. Bolognesi, M.L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, C., Alzheimer's disease: New approaches to drug discovery. Curr. Opin. Chem. Biol., 2009, 13(3), 303-308.
85. Bolognesi, M.L.; Rosini, M.; Andrisano, V.; Bartolini, M.; Minarini, A.; Tumiatti, V.; Melchiorre, C., MTDL design strategy in the context of Alzheimer's disease: From lipocrine to memoquin and beyond. Curr. Pharm. Des., 2009, 15(6), 601-613.
86. Bolognesi, M.L.; Cavalli, A.; Melchiorre, C., Memoquin: A multitarget-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics, 2009, 6(1), 152-162.
87. Tumiatti, V.; Milelli, A.; Minarini, A.; Rosini, M.; Bolognesi, M.L.; Micco, M.; Andrisano, V.; Bartolini, M.; Mancini, F.; Recanatini, M.; Cavalli, A.; Melchiorre, C., Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. J. Med. Chem., 2008, 51(22), 7308-7312.
88. Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Melchiorre, C., From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): A step forward in the treatment of Alzheimer's disease. Mini Rev. Med. Chem., 2008, 8(10), 960-967.
89. Bolognesi, M.L.; Calonghi, N.; Mangano, C.; Masotti, L.; Melchiorre, C., Parallel synthesis and cytotoxicity evaluation of a polyamine-quinone conjugates library. J. Med. Chem., 2008, 51(17), 5463-5467.
90. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D.W.; Tarozzi, A.; Bolognesi, M.L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I.R.; Melchiorre, C., Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: A promising direction for the multi-target-directed ligands gold rush. J. Med. Chem., 2008, 51(15), 4381-4384.
91. Melchiorre, C.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V., Polyamines in drug discovery: From the universal template approach to the multitarget-directed ligand design strategy. J. Med. Chem., 2010, 53(16), 5906-5914.
92. Bolognesi, M.L.; Bartolini, M.; Tarozzi, A.; Morroni, F.; Lizzi, F.; Milelli, A.; Minarini, A.; Rosini, M.; Hrelia, P.; Andrisano, V.; Melchiorre, C., Multitargeted drugs discovery: Balancing antiamyloid and anticholinesterase capacity in a single chemical entity. Bioorg. Med. Chem. Lett., 2011, 21(9), 2655-2658.
93. Bongarzone, S.; Tran, H.N.; Cavalli, A.; Roberti, M.; Carloni, P.; Legname, G.; Bolognesi, M.L., Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J. Med. Chem., 2010, 53(22), 8197-8201.
94. Simoni, E.; Bergamini, C.; Fato, R.; Tarozzi, A.; Bains, S.; Motterlini, R.; Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Hrelia, P.; Lenaz, G.; Rosini, M.; Melchiorre, C., Polyamine conjugation of curcumin analogues toward the discovery of mitochondriadirected neuroprotective agents. J. Med. Chem., 2010, 53(19), 7264-7268.
95. Rolinski, M.; Fox, C.; Maidment, I.; McShane, R., Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev, 2012, 3, CD006504.
96. Salomone, S.; Caraci, F.; Leggio, G.M.; Fedotova, J.; Drago, F., New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease modifying drugs. Br. J. Clin. Pharmacol., 2012, 73(4), 504-517.
97. Hoy, S.M.; Keating, G.M., Rasagiline: A review of its use in the treatment of idiopathic Parkinson's disease. Drugs, 2012, 72(5), 643-669.
98. Zheng, H.; Amit, T.; Bar-Am, O.; Fridkin, M.; Youdim, M.B.; Mandel, S.A., From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. J. Alzheimers Dis., 2012, 30(1), 1-16.
99. Weinreb, O.; Amit, T.; Riederer, P.; Youdim, M.B.; Mandel, S.A., Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Int. Rev. Neurobiol., 2011, 100, 127-149.
100. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B., Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol., 2010, 92(3), 330-344.
101. Youdim, M.B.; Gross, A.; Finberg, J.P., Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol., 2001, 132(2), 500-506.
102. Lew, M.F., The evidence for disease modification in Parkinson's disease. Int. J. Neurosci., 2011, 121 Suppl 2, 18-26.
103. Rascol, O.; Fitzer-Attas, C.J.; Hauser, R.; Jankovic, J.; Lang, A.; Langston, J.W.; Melamed, E.; Poewe, W.; Stocchi, F.; Tolosa, E.; Eyal, E.; Weiss, Y.M.; Olanow, C.W., A double-blind, delayedstart trial of rasagiline in Parkinson's disease (the ADAGIO study): Prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol., 2011, 10(5), 415-423.
104. Jenner, P.; Langston, J.W., Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline. Mov. Disord., 2011, 26(13), 2316-2323.
105. Bar-Am, O.; Amit, T.; Weinreb, O.; Youdim, M.B.; Mandel, S., Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: Involvement of MAPK and PKC activation. J. Alzheimers Dis., 2010, 21(2), 361-371.
106. Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M.B., Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J., 2005, 19(13), 1899-1901.
107. Weinreb, O.; Amit, T.; Bar-Am, O.; Chillag-Talmor, O.; Youdim, M.B., Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: Interaction of Bcl-2 family members with PKC pathway. Ann. N. Y. Acad. Sci., 2005, 1053, 348-355.
108. Weinreb, O.; Amit, T.; Bar-Am, O.; Sagi, Y.; Mandel, S.; Youdim, M.B., Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl., 2006, (70), 457-465.
109. Weinstock, M.; Bejar, C.; Wang, R.H.; Poltyrev, T.; Gross, A.; Finberg, J.P.; Youdim, M.B., TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural. Transm. Suppl., 2000, (60), 157-169.
110. Zhou, X.; Patel, A.R.; Perez, F.; Jurivich, D.A., Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines. Transl. Res., 2009, 153(3), 132-141.
111. Bar-Am, O.; Amit, T.; Youdim, M.B., Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem., 2007, 103(2), 500-508.
112. Bar-Am, O.; Yogev-Falach, M.; Amit, T.; Sagi, Y.; Youdim, M.B., Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem., 2004, 89(5), 1119-1125.
113. Youdim, M.B.; Amit, T.; Bar-Am, O.; Weinstock, M.; Yogev-Falach, M., Amyloid processing and signal transduction properties of antiparkinson- antialzheimer neuroprotective drugs rasagiline and TV3326. Ann. N. Y. Acad. Sci., 2003, 993, 378-386; discussion 387-393.
114. Youdim, M.B.; Weinstock, M., Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(Npropargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol., 2001, 21(6), 555-573.
115. Bruhlmann, C.; Ooms, F.; Carrupt, P.A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A., Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem., 2001, 44(19), 3195-3198.
116. Bolea, I.; Juarez-Jimenez, J.; de Los Rios, C.; Chioua, M.; Pouplana, R.; Luque, F.J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A., Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl- 1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem., 2011, 54(24), 8251-8270.
117. Huang, L.; Lu, C.; Sun, Y.; Mao, F.; Luo, Z.; Su, T.; Jiang, H.; Shan, W.; Li, X., Multi-target-directed Benzylidene-indanone derivatives: Anti-beta Amyloid (Abeta) aggregation, Antioxidant, Metal chelation and Monoamine oxidase B (MAO-B) Inhibition Properties Against Alzheimer's disease. J. Med. Chem., 2012, 55(19), 8483-8492.
118. Kozikowski, A.P.; Chen, Y.; Subhasish, T.; Lewin, N.E.; Blumberg, P.M.; Zhong, Z.; D'Annibale, M.A.; Wang, W.L.; Shen, Y.; Langley, B., Searching for disease modifiers-PKC activation and HDAC inhibition-A dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. ChemMedChem, 2009, 4(7), 1095-1105.
119. Skovronsky, D.M.; Moore, D.B.; Milla, M.E.; Doms, R.W.; Lee, V.M., Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem., 2000, 275(4), 2568-2575.
120. Jolly-Tornetta, C.; Wolf, B.A., Protein kinase C regulation of intracellular and cell surface amyloid precursor protein (APP) cleavage in CHO695 cells. Biochemistry, 2000, 39(49), 15282-15290.
121. Gray, S.G.; Dangond, F., Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics, 2006, 1(2), 67-75.
122. Morphy, R.; Rankovic, Z., Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15(6), 587-600.
123. Braymer, J.J.; Detoma, A.S.; Choi, J.S.; Ko, K.S.; Lim, M.H., Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-beta Species in Alzheimer's Disease. Int. J. Alzheimers Dis., 2010, 2011, 623051.